Pharming Group announces publication of its Annual Report 2018 and a provisional commitment to invest in supplier
Pharming Group N.V. announces publication of its Annual Report for the financial year ended 31 December 2018. The Company also announces that it has made a provisional commitment to invest up to €1.6 million in cash and convert €2.5 million of prepayments into equity in its fill & finish partner BioConnection BV, which manufactures the final sealed vials of Pharming’s product RUCONEST® from the purified drug substance.
- Annual Report 2018 is available for download on the Pharming website today at www.pharming.com/investors/financial-documents
- Printed copies will be available from mid-April upon application to email@example.com
- Pharming also announces a provisional commitment to invest in a minority stake in its fill & finish partner BioConnection BV
“BioConnection has been an excellent partner for Pharming for many years, and is an important part of our future plans."- Sijmen de Vries - CEO